Prof. Dr. Ernst von Schwarz is a world-renowned researcher and clinical and academic cardiologist, who has published more than 150 scientific articles in international peer-reviewed journals, several books’ chapters, and books. He is also a sought-after speaker at international scientific conferences worldwide, an expert on stem cell therapy and research, and a public figure in medical media.
Human umbilical cord tissue-derived (HUCT) mesenchymal stem cells are less likely to be rejected by the immune system, so there is no need to worry about cell rejection or matching Human Leukocyte Antigen (HLA).
Allogeneic stem cells can be given several times over a few days in consistent doses with high cell counts.
The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
Umbilical cord tissue offers mesenchymal stem cells vital for regenerative medicine. Easily harvested after childbirth, it provides abundant, low-risk stem cells with promising medical applications.
There's no need to take stem cells from the patient's hip bone or fat while they're under anesthesia, which can be especially tough for small children and their parents.
There is a growing body of evidence showing that HUCT mesenchymal stem cells are more robust than mesenchymal stem cells from other sources.
There is no need to give chemotherapy drugs like Granulocyte-colony stimulating factor (G-CSF) to help the bone marrow make granulocytes and stem cells and release them into the bloodstream.
We use Elite Cells™. Years-long retrospective analysis of patient outcomes has enabled us to identify and select the best cells for use in our patients.
A staff physician will assign a stem cell treatment protocol after you have submitted all requested medical information and received approval. Your recommended protocol may differ from the example given below:
Note: Includes Hilton hotel room with breakfast, WIFI, transportation from and to the airport with VIP airport gate service and expedited customs clearance upon arrival.
No stem cell product from any source, including the patient’s own, is approved by the US FDA to treat autoimmune disease.
However, human umbilical cord tissue-derived mesenchymal stem cells that were isolated and grown in our laboratory in Barranquilla, Colombia to create master cell banks have been used in the United States under US FDA regulation.
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign, and therefore they are not rejected.
Human umbilical cord tissue stem cells have been administered tens of thousands of times at the NovaCell Institute and there has never been a single instance of rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat, and therefore, they are considered to be more “potent”.
The adult stem cells used to treat autoimmune disease at the NovaCell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Barranquilla, Colombia’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births. Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Proper follow-up is an essential part of stem cell therapy. Our primary goal is to ensure that your child is progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, 9 months, and 1 year to monitor your child’s progress.
You can APPLY TODAY to find out if you are eligible for treatment, and a patient coordinator will reach out to will arrange for a free screening and consultation.
NovaCell Regenerative Medicine by Belleza
Cra 59B 81-143
Barranquilla, Colombia
Outside or Inside US Call:
Phone: +1 (754) 333-6754
Copyright 2026, NovaCell Institute in Barranquilla, Colombia. All rights reserved.
